BOSTON SCIENTIFIC CORP
BSXAPI behind this page
BSX FY 2025 request
Playground key active
/api/financials?ticker=BSX&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 20,074 | 16,747 | +19.9% |
Show Product Lines breakouts |
|||
| Cardiac Rhythm Management · Non Us | 907 | 876 | +3.5% |
| Cardiac Rhythm Management · Operating Segments | 2,332 | 2,279 | +2.3% |
| Cardiac Rhythm Management · US | 1,425 | 1,403 | +1.6% |
| Electrophysiology · Non Us | 1,014 | 648 | +56.5% |
| Electrophysiology · Operating Segments | 3,325 | 1,904 | +74.6% |
| Electrophysiology · US | 2,311 | 1,256 | +84.0% |
| Endoscopy · Non Us | 1,115 | 1,036 | +7.6% |
| Endoscopy · Operating Segments | 2,916 | 2,687 | +8.5% |
| Endoscopy · US | 1,802 | 1,651 | +9.1% |
| Interventional Cardiology & Vascular Therapies · Non Us | 2,632 | 2,592 | +1.5% |
| Interventional Cardiology & Vascular Therapies · Operating Segments | 4,639 | 4,199 | +10.5% |
| Interventional Cardiology & Vascular Therapies · US | 2,007 | 1,607 | +24.9% |
| Interventional Oncology & Embolization · Non Us | 381 | 338 | +12.7% |
| Interventional Oncology & Embolization · Operating Segments | 996 | 856 | +16.4% |
| Interventional Oncology & Embolization · US | 615 | 518 | +18.7% |
| Neuromodulation · Non Us | 285 | 259 | +10.0% |
| Neuromodulation · Operating Segments | 1,199 | 1,106 | +8.4% |
| Neuromodulation · US | 914 | 847 | +7.9% |
| Urology · Non Us | 709 | 643 | +10.3% |
| Urology · Operating Segments | 2,709 | 2,200 | +23.1% |
| Urology · US | 2,000 | 1,557 | +28.5% |
| Watchman · Non Us | 167 | 145 | +15.2% |
| Watchman · Operating Segments | 1,958 | 1,516 | +29.2% |
| Watchman · US | 1,791 | 1,371 | +30.6% |
Show Business Segments breakouts |
|||
| Cardiovascular · Non Us | 5,101 | 4,599 | +10.9% |
| Cardiovascular · Operating Segments | 13,250 | 10,755 | +23.2% |
| Cardiovascular · US | 8,149 | 6,156 | +32.4% |
| MedSurg · Non Us | 2,108 | 1,939 | +8.7% |
| MedSurg · Operating Segments | 6,824 | 5,993 | +13.9% |
| MedSurg · US | 4,715 | 4,054 | +16.3% |
Show Geography breakouts |
|||
| Asia Pacific | 3,080 | 2,686 | +14.7% |
| EMEA | 3,451 | 3,228 | +6.9% |
| Emerging Markets | 2,985 | 2,680 | +11.4% |
| Latin America and Canada | 678 | 624 | +8.7% |
| Non Us | 7,210 | 6,538 | +10.3% |
| US | 12,864 | 10,210 | +26.0% |
| Cost of Revenue | 6,221 | 5,257 | +18.3% |
| Gross Profit | 13,854 | 11,490 | +20.6% |
| Selling, General & Administrative | 6,887 | 5,984 | +15.1% |
| Research And Development Expense Excluding Acquired In Process Cost | 2,052 | 1,615 | +27.1% |
| Royalty Expense | 46 | 33 | +39.4% |
| Amortization Of Intangible Assets | 897 | 856 | +4.8% |
| Impairment Of Intangible Assets Excluding Goodwill | 46 | 386 | -88.1% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 18 | -5 | +460.0% |
| Restructuring Charges | 101 | 16 | +531.2% |
| Litigation Settlement Expense | 194 | — | — |
| Operating Expenses | 10,241 | 8,887 | +15.2% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 958 | 788 | +21.6% |
| Operating Income | 3,613 | 2,603 | +38.8% |
| Interest Expense | -349 | -305 | -14.4% |
| Other Nonoperating Income Expense Net | 121 | -16 | +856.2% |
| Income Before Taxes | 3,385 | 2,282 | +48.3% |
| Income Tax Expense (Benefit) | 493 | 436 | +13.1% |
| Net Income | 2,892 | 1,846 | +56.7% |
Show Equity Components breakouts |
|||
| Retained Earnings | 2,892 | 1,846 | +56.7% |
| Net Income Loss Attributable To Noncontrolling Interest | -6 | -8 | +25.0% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | -6 | -8 | +25.0% |
| Net Income Loss Available To Common Stockholders Basic | 2,898 | 1,853 | +56.4% |
| EPS (Basic) | 1.96 | 1.26 | +55.6% |
| EPS (Diluted) | 1.94 | 1.25 | +55.2% |
| Wtd Avg Shares (Basic) | 1,480.4 | 1,471.5 | +0.6% |
| Wtd Avg Shares (Diluted) | 1,494.5 | 1,485.9 | +0.6% |
| Other Non-Operating Income (Expense) | -228 | -321 | +29.0% |
| Comprehensive Income | 2,013 | 2,079 | -3.2% |
| Foreign Currency Transaction Gain Loss Before Tax (FY) | — | — | — |
Show Hedging Designation breakouts |
|||
| Nondesignated · Other Nonoperating Income Expense | 162 | -71 | +328.2% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (FY) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract · Designated As Hedging Instrument | -145 | 142 | -202.1% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,965 | 414 | +374.6% |
| Accounts Notes And Loans Receivable Net Current | 2,926 | 2,558 | +14.4% |
| Inventory | 2,943 | 2,810 | +4.7% |
| Prepaid Taxes | 299 | 307 | -2.6% |
| Prepaid Expenses & Other Current Assets | 660 | 831 | -20.6% |
| Total Current Assets | 8,794 | 6,920 | +27.1% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 4,036 | 3,294 | +22.5% |
| Goodwill | 18,282 | 17,089 | +7.0% |
Show Business Segments breakouts |
|||
| Cardiovascular | 10,574 | 9,606 | +10.1% |
| MedSurg | 7,709 | 7,483 | +3.0% |
Show Business Acquisition breakouts |
|||
| All Other | 507 | — | — |
| Deferred Tax Assets | 3,675 | 3,655 | +0.5% |
| Other Non-Current Assets | 1,866 | 1,754 | +6.4% |
| Total Assets | 43,673 | 39,395 | +10.9% |
| Operating Lease Right-of-Use Assets | 465 | 449 | +3.6% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 7,019 | 6,684 | +5.0% |
| Current Liabilities | |||
| Debt Current | 299 | 1,778 | -83.2% |
| Accounts Payable | 1,144 | 960 | +19.2% |
| Accrued Liabilities | 3,201 | 2,773 | +15.4% |
| Other Liabilities Current | 795 | 887 | -10.4% |
| Total Current Liabilities | 5,439 | 6,399 | -15.0% |
| Deferred Revenue | 313 | 306 | +2.3% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 220 | 155 | +41.9% |
| Other Non-Current Liabilities | 2,405 | 1,870 | +28.6% |
| Long-Term Debt (Q) | — | — | — |
Show Long-Term Debt Type breakouts |
|||
| Capital Lease Obligations | 125 | 126 | -0.8% |
| December 2027 Notes | 1,058 | 935 | +13.2% |
| January 2040 Notes | 300 | 300 | 0.0% |
| June 2030 Notes | 1,200 | 1,200 | 0.0% |
| March 2028 Notes | 344 | 344 | 0.0% |
| March 2028 Senior Notes | 881 | 779 | +13.1% |
| March 2029 Euro Senior Notes | 881 | 779 | +13.1% |
| March 2029 Notes | 272 | 272 | 0.0% |
| March 2031 Notes | 881 | 779 | +13.1% |
| March 2031 Notes 2 | 999 | — | — |
| March 2032 Euro Senior Notes | 1,469 | 1,299 | +13.1% |
| March 2034 Notes | 588 | 519 | +13.3% |
| March 2034 Notes 2 | 764 | — | — |
| March 2039 Notes | 450 | 450 | 0.0% |
| March 2049 Notes | 650 | 650 | 0.0% |
| November 2019 Aggregate Offering | 900 | 900 | 0.0% |
| November 2035 Notes | 350 | 350 | 0.0% |
| Senior Notes | 11.34 | 10.45 | +8.5% |
| Operating Lease Liabilities | 446 | 401 | +11.2% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 11,137 | 8,968 | +24.2% |
| Minority Interest | 239 | 233 | +2.6% |
| Stockholders' Equity | |||
| Common Stock | 17 | 17 | 0.0% |
| Treasury Stock Value | -2,251 | -2,251 | 0.0% |
| Additional Paid In Capital Common Stock | 21,505 | 21,056 | +2.1% |
| Retained Earnings | 5,571 | 2,673 | +108.4% |
| Accumulated Other Comprehensive Income | -610 | 275 | -321.8% |
| Total Stockholders' Equity | 24,233 | 21,770 | +11.3% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -2 | -16 | +87.5% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -48 | 155 | -131.0% |
| Accumulated Other Comprehensive Income | -610 | 275 | -321.8% |
| Accumulated Translation Adjustment | -561 | 136 | -512.5% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 24,472 | 22,003 | +11.2% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -610 | 275 | -321.8% |
| Additional Paid In Capital | 21,505 | 21,056 | +2.1% |
| Common Stock | 17 | 17 | 0.0% |
| Noncontrolling Interest | 239 | 233 | +2.6% |
| Parent | 24,233 | 21,770 | +11.3% |
| Retained Earnings | 5,571 | 2,673 | +108.4% |
| Treasury Stock Common | -2,251 | -2,251 | 0.0% |
| Total Liabilities & Equity | 43,673 | 39,395 | +10.9% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 1,368 | 1,269 | +7.8% |
| Cash Flow Impact Of Deferred Income Tax Expense Benefit | -2 | -70 | +97.1% |
| Stock-Based Compensation | 299 | 266 | +12.4% |
Show Income Statement Location breakouts |
|||
| Cost Of Sales | 16 | 14 | +14.3% |
| Research And Development Expense | 53 | 46 | +15.2% |
| Selling General And Administrative Expenses | 231 | 206 | +12.1% |
| Impairment Of Intangible Assets Indefinitelived Excluding Goodwill | 46 | 386 | -88.1% |
| Gain Loss On Investments | -139 | 79 | -275.9% |
| Inventory Step Up Amortization | 132 | 51 | +158.8% |
| Tangible Asset Impairment Charges | 124 | 72 | +72.2% |
| Other Operating Activities Cash Flow Statement | 42 | 2 | +2000.0% |
| Change in Accounts Receivable | -269 | -351 | +23.4% |
| Change in Inventory | -188 | -228 | +17.5% |
| Increase Decrease In Other Operating Assets | -85 | -126 | +32.5% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 296 | 243 | +21.8% |
| Net Cash from Operations | 4,534 | 3,435 | +32.0% |
| Deferred Income Taxes | -12 | -90 | +86.7% |
| Investing Activities | |||
| Capital Expenditures | -876 | -790 | -10.9% |
| Payments To Acquire Businesses Net Of Cash Acquired | -1,593 | -4,640 | +65.7% |
Show Business Acquisition breakouts |
|||
| All Other | -756 | — | — |
| Other 2025 Acquisitions | -162 | — | — |
| Proceeds From Payments For Investments And Acquisitions Of Certain Technologies | -254 | -280 | +9.3% |
| Other Investing Activities | 84 | 23 | +265.2% |
| Net Cash from Investing | -2,640 | -5,687 | +53.6% |
| Financing Activities | |||
| Payment For Contingent Consideration Liability Financing Activities | -62 | -131 | +52.7% |
| Finance Lease Principal Payments | -258 | -25 | -932.0% |
| Repayments Of Short Term Debt | -1,595 | -504 | -216.5% |
| Proceeds From Repayments Of Commercial Paper | -196 | 187 | -204.8% |
| Proceeds From Issuance Of Senior Long Term Debt | 1,558 | 2,145 | -27.4% |
| Paymenttonetsharesettleemployeeequityawards | -131 | -87 | -50.6% |
| Proceeds From Stock Plans | 282 | 230 | +22.6% |
| Proceeds From Payments For Other Financing Activities | 7 | -1 | +800.0% |
| Net Cash from Financing | -395 | 1,814 | -121.8% |
| Supplemental | |||
| Income Taxes Paid | 561 | 656 | -14.5% |
| Interest Paid | 319 | 250 | +27.6% |
| Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases | 258 | 29 | +789.7% |
| Right Of Use Asset Obtained In Exchange For Finance Lease Liability | 205 | 122 | +68.0% |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 119 | 117 | +1.7% |
| Restricted Cash And Cash Equivalents At Carrying Value | 80 | 111 | -27.9% |
| Restricted Cash Equivalents Noncurrent | 103 | 80 | +28.7% |
| Income Taxes Paid | 561 | — | — |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 42 | -11 | +481.8% |
| Net Change in Cash | 1,541 | -450 | +442.4% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,147 | 606 | +254.3% |
Values in millions USD. Source: SEC EDGAR 10-K filing.